UGISense and Boehringer Ingelheim enter into an agreement for specific Ugimers™ in animal parasitic diseases

Dortmund, Germany, March 15th, 2022 – UGISense AG today announces that it entered into an agreement with Boehringer Ingelheim, a global leader in animal health, to collaborate on the research in the field of animal parasitic diseases.

Under the agreement, UGISense will provide parasite-specific Ugimers™ to Boehringer Ingelheim. These Ugimers™ will be tested in models for parasitic diseases with high relevance to evaluate their ability to suppress parasite development and maturation.

Dr. Birgit Werner and Dr. Thomas Lindhorst, Managing Directors of UGISense said: “While we understand the efficacy of Ugimers™ quite well in human diseases like cancer, metabolic diseases and neurology, the animal disease application is new to us.

It will be very interesting to see the Ugimer™ potential in the field of parasite diseases as these diseases have a high relevance in pet as well as in farm animal segments.”

No financial details were disclosed.

About UGISense AG

UGISense AG is a biotechnology company dedicated to developing Ugimers™ a new innovative type of antisense drugs.  To leverage the potential of the Ugimer™ technology, UGISense AG has set up programs in the fields of oncology, rare muscular dystrophies, peripheral neuropathies, metabolic diseases, and kidney diseases.

The company is situated in Dortmund/Germany and financed by private investors, the Lead Discovery Center Dortmund GmbH and Seed Capital II GmbH.

About UgimersTM

UgimersTM are short peptidic oligonucleotide sequences capable of interacting with single-stranded DNA or RNA by forming a double strand. Due to such double-strand formation, disease-relevant proteins will be specifically prevented from forming at all or will be reduced to a modified stage. This mechanism achieves a therapeutic influence on diseases at a very early stage of intervention. Structurally, UgimersTM are derived from peptide nucleic acids (PNAs) to which important pharmacological functions have been added by way of chemical modifications.

For closer detail visit


T.: +49 – 231 – 9742 70063

About Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit: